ClinicalTrials.gg
Status unknownNCT05263986Updated Feb 27, 2023

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of MRTX849 in Advanced or Metastatic Solid Tumor, sponsored by Zai Lab (Shanghai) Co., Ltd.. Status unknown at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-27.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Enrollment
350th of 401
22 · median 90
Started
2022
with 44 others
Phase 1
93 of 485
47 open now
Registered
218th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 350th largest by enrollment of the 401 interventional ones that give a count, is one of 45 that started in 2022, is one of 93 in phase 1, and was the 218th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This is a phase 1, open-label, single-arm study in Chinese patients with unresectable, locally advanced or metastatic solid tumor with KRAS G12C mutation, for which treatment with curative intent is not available.

Patients must have a documented KRAS G12C mutation determined by tissue or liquid-based local testing.

The PK profile of MRTX849 in Chinese patients will be evaluated after administration of a single and repeat oral doses of 600 mg BID. In the PK lead-in period, blood samples will be collected pre-dose and up to 96 hours post a single oral dose of 600 mg MRTX849. Following this lead-in period, patients will start the dosing regimen of 600 mg BID orally, and blood samples will be collected pre-dose and up to 12 hours after multiple doses of MRTX849 600 mg BID on Cycle 1 Day 8 (C1D8).

Safety including AEs, ECGs, laboratory parameters and vital signs of each patient will be monitored throughout the conduct of the study.

Disease response and progression will be evaluated in accordance with Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).

03

Conditions studied

  • Advanced or Metastatic Solid Tumor

Browse trials for

Keywords

  • KRAS G12C mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. confirmed diagnosis of a solid tumor with KRAS G12C mutation.

      1. Unresectable or disease.
      1. Available therapy:
      2. no available treatment with curative intent,
      3. no available standard-of-care treatment or patient is ineligible or declines treatment.

        1. Presence of measurable or non- per 1.1.
        1. Age ≥ 18 years.
        1. of at least 3 months.
        1. Most recent prior systemic therapy (e.g., chemotherapy, immunotherapy, or agent) and radiation therapy discontinued at least 2 weeks before first dose date.
        1. Recovery from the adverse effects of prior therapy at the time of enrollment to ≤ Grade 1 (excluding alopecia).
        1. (ECOG) performance status of 0 or 1.
        1. Laboratory values within the ranges below during the screening period:

      <!-- -->

      1. ≥ 1,000/mm3 (≥ 1.0 x 109/L)
      2. count ≥ 100,000/mm3 (≥ 100 x 109/L)
      3. ≥ 9 g/dL, in the absence of transfusions for at least 2 weeks
      4. Total ≤ 1.5 x (ULN) (if associated with liver metastases or Gilbert's disease, ≤ 3 x ULN)
      5. (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN (if associated with liver metastases, ≤ 5 x ULN)
      6. (CrCl) ≥ 60 mL/min.

        1. Women of (WOCBP) or men whose partner is a WOCBP agree to use while participating in this study, and for a period of 6 months following termination of study treatment.
        1. Completed process, including signing Ethics Committee (EC)-approved informed consent form.
        1. Willing to comply with clinical trial instructions and requirements.

Exclusion criteria

Exclusion Criteria:

    1. Use of the treatment known to cause prolonged interval (QTc) or with a known risk of Torsades de Pointes that cannot be switched to alternative treatment within 5 half-lives prior to MRTX849 dosing initiation

      1. Use of any drugs or substances including herbal supplements known or suspected to alter MRTX849 absorption, distribution, metabolism, or excretion:
      2. Inhibitors of , CYP2C8, P-glycoprotein (P-gp), or breast cancer resistance protein (BCRP) within 7 days or 5 half-lives, whichever is longer, prior to MRTX849 dosing initiation.
      3. Inducers of CYP3A4 or CYP2C8 within 14 days or 5 half-lives, whichever is longer, prior to MRTX849 dosing initiation.
      4. Proton-pump inhibitors within 7 days or 5 half-lives, whichever is longer, prior to MRTX849 dosing initiation.

        1. Active or carcinomatous meningitis. Patients are eligible if brain metastases are adequately treated and patients are neurologically stable for at least 2 weeks prior to study entry without the use of or are on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
        1. History of significant hemoptysis or hemorrhage within 4 weeks prior to MRTX849 dosing initiation.
        1. Any of the following cardiac abnormalities:

      <!-- -->

      1. Unstable angina pectoris or myocardial infarction within 6 months prior to

        MRTX849 dosing initiation.

      2. Symptomatic or uncontrolled atrial fibrillation within 6 months prior to

        MRTX849 dosing initiation.

      3. Congestive heart failure ≥ (NYHA) Class 3 within 6 months prior to MRTX849 dosing initiation.
      4. Prolonged QTc interval > 480 milliseconds.

        1. History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications.
        1. Known (HIV) infection or acute or chronic or C infection. Note that the following are permitted:

      <!-- -->

      1. Patients treated for (HCV) with no detectable viral load;
      2. Patients treated for HIV with no detectable viral load for at least 1 month prior to study entry while on a stable regimen of agents that are not strong inhibitors of CYP3A4; and
      3. Patients with hepatitis B (HBV) receiving prophylaxis against reactivation of hepatitis B (either [HBsAg-positive with normal and HBV DNA \<2,000 IU/mL or \<10,000 copies/mL] or [HBsAg-negative and anti-HBc-positive]).

        1. Major surgery within 4 weeks prior to MRTX849 dosing initiation.
        1. History of stroke or within 6 months prior to MRTX849 dosing initiation.
        1. Known or suspected presence of another that could be mistaken for the malignancy under study during disease assessments.
        1. Pregnancy. must have a negative serum or urine pregnancy test documented within the screening period prior to MRTX849 dosing initiation.
        1. Breast-feeding or planning to breast feed during the study or within 6 months after study treatment with MRTX849.
        1. Any serious illness, uncontrolled intercurrent illness, psychiatric illness, active or uncontrolled infection, or other medical history, including laboratory results, which, in the Investigator's opinion, would be likely to interfere with the patient's participation in the study, or with the interpretation of the results.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Assigned Interventions

    In the 5-day PK lead-in period, patients will receive a single oral dose of 600 mg MRTX849 on Day 1 and there will be no drug administration in the subsequent 4 days. Following the PK lead-in period, patients will receive MRTX849 600 mg BID (an interval of approximate 12 hours between 2 doses) orally in 3-week cycles until disease progression, unacceptable AEs, patient refusal, or death. Dosing schedules may be adjusted depending on safety results.

    Drug: MRTX849

Interventions

  • Approximately 18-24 patients to ensure at least 12 PK evaluable patients. Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1.

06

What researchers measure

Primary outcomes

  1. Main PK parameters: Cmax

    Maximum plasma concentration (Cmax) after single dose

    Time frame: Approximately 2 weeks after dose initiation

  2. Main PK parameters: Tmax

    Maximum plasma concentration (Tmax) after single dose

    Time frame: Approximately 2 weeks after dose initiation

  3. Main PK parameters: AUC0-12

    Area under the concentration-time curve from time 0 to 12 hours (AUC0-12) after single dose

    Time frame: Approximately 12 hours after dose initiation

  4. Main PK parameters: AUC0-t

    Area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-t) after single dose

    Time frame: Approximately 2 weeks after dose initiation

  5. Main PK parameters: AUC0-∞

    Area under the concentration-time curve from time 0 to infinity (AUC0-∞) after single dose

    Time frame: Approximately 2 weeks after dose initiation

  6. Main PK parameters: t1/2

    Terminal half-life (t1/2) after single dose

    Time frame: Approximately 2 weeks after dose initiation

  7. Main PK parameters: CL/F

    Apparent clearance (CL/F) after single dose

    Time frame: Approximately 2 weeks after dose initiation

  8. Main PK parameters: Vz/F

    Apparent volume of distribution associated with the terminal phase (Vz/F) after single dose

    Time frame: Approximately 2 weeks after dose initiation

  9. Main PK parameters: Cmax, ss

    Maximum plasma concentration at steady state (Cmax, ss)

    Time frame: Approximately 2 weeks after dose initiation

  10. Main PK parameters: Tmax, ss

    Time to observed maximum plasma concentration at steady state (Tmax, ss)

    Time frame: Approximately 2 weeks after dose initiation

  11. Main PK parameters: Cmin, ss

    Trough concentration (Cmin, ss)

    Time frame: Approximately 2 weeks after dose initiation

  12. Main PK parameters: Cavg

    Average concentration during a dosing interval (Cavg)

    Time frame: Approximately 2 weeks after dose initiation

  13. Main PK parameters: AUCss

    Area under the concentration-time curve at steady state (AUCss)

    Time frame: Approximately 2 weeks after dose initiation

  14. Main PK parameters: Rac for Cmax and AUCtau

    Accumulation ratio (Rac for Cmax and AUCtau)

    Time frame: Approximately 2 weeks after dose initiation

  15. Main PK parameters: PTR

    Peak-to-trough ratio (PTR)

    Time frame: Approximately 2 weeks after dose initiation

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0

    Time frame: Approximately 12 months after dose initiation

  2. Incidence of Treatment-Emergent Serious Adverse Events

    Incidence of Treatment-Emergent Serious Adverse Events as assessed by CTCAE v5.0

    Time frame: Approximately 12 months after dose initiation

  3. Incidence of Treatment-Related Adverse Events

    Incidence of Treatment-Related Adverse Events as assessed by CTCAE v5.0

    Time frame: Approximately 12 months after dose initiation

  4. Incidence of Treatment-Related Serious Adverse Events

    Incidence of Treatment-Related Serious Adverse Events as assessed by CTCAE v5.0

    Time frame: Approximately 12 months after dose initiation

  5. Incidence of abnormal laboratory value

    Incidence of abnormal laboratory value is defined as the proportion of patients who have abnormal laboratory value not prior to the dose initiation of MRTX849

    Time frame: Approximately 12 months after dose initiation

Other outcomes

  1. Objective response rate (ORR)

    Objective Response Rate (ORR) as assessed by Investigator per RECIST v1.1 Duration of response (DOR)

    Time frame: Approximately 12 months after dosed

  2. Duration of response (DOR)

    Duration of Response (DOR) is defined as the time from radiographic response to disease progression in patients with a best response of CR or PR, assessed per RECIST 1.1

    Time frame: Approximately 12 months after dosed

07

Study locations

8 sites
  • Beijing Cancer Hospital
    Beijing, Beijing, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Union hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • The first Hospital of Jilin University
    Changchun, Jilin, China
  • Lin Yi Cancer Hospital
    Linyi, Shandong, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Oct 2023, 17 months after the start.

Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 17 months is below that.

Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Mar 3, 2022
StartActual
May 30, 2022
Primary completionEst.
Oct 31, 2023
CompletionEst.
Oct 31, 2023
Last update
Feb 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05263986
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
May 30, 2022
Primary completion
Oct 31, 2023 (estimated)
Completion
Oct 31, 2023 (estimated)
Last update
Feb 27, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adagrasib

Start the discussion